Related Experiment Video
Updated: Sep 26, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Human embryonic stem cells for cardiovascular repair
Sharon Gerecht Nir1, Robert David, Marc Zaruba
1Biotechnology Interdisciplinary Unit, Technion-Israel Institute of Technology, Haifa, Israel.
Insights
Regenerating heart tissue is crucial for treating heart failure. This review explores using human embryonic stem cells to create new cardiomyocytes and vascular cells for cardiac repair.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Stem Cell Biology
Background:
- Loss of functional cardiomyocytes leads to heart failure.
- Adult cardiomyocytes do not regenerate, limiting treatment options.
- Current therapies for end-stage heart failure are insufficient.
Purpose of the Study:
- To review the therapeutic potential of human embryonic stem (hES) cell-derived cells for heart repair.
- To discuss the application of hES cell-derived cardiomyocytes and vascular cells in treating myocardial infarction and heart failure.
Main Methods:
- Literature review focusing on stem cell therapy for cardiac regeneration.
- Analysis of studies investigating hES cell differentiation into cardiomyocytes and vascular cells.
- Evaluation of the potential clinical applications of these cell types.
Main Results:
- Human embryonic stem cells can differentiate into functional cardiomyocytes and vascular cells.
- These cells hold promise for regenerating damaged cardiac tissue.
- Stem cell-based therapy offers a potential new avenue for treating heart failure.
Conclusions:
- Human embryonic stem cell-derived cells represent a promising therapeutic strategy for heart failure.
- Further research is needed to optimize cell delivery and integration for clinical application.
- Stem cell therapy could revolutionize the treatment of ischemic heart disease and end-stage heart failure.
Abstract:
The critical loss of functional cardiomyocytes causes severe deterioration of pump function, resulting in heart failure. The possibility to regenerate or repair damaged or ischemic cardiac tissue is a great challenge for the future treatment of end-stage heart failure. As cardiomyocytes cannot be regenerated in adults, current therapeutic modalities for the treatment of end-stage heart failure are limited and include medical therapy, mechanical left ventricular assist devices, and cardiac transplantation. This review will focus on the potential use of human embryonic stem (hES) cell-derived cardiomyocytes and vascular cells, as a therapeutic tool for the treatment of myocardial infarction and end-stage heart failure.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Embryonic Stem Cells
Stem Cell Culture
Adult Stem Cells
iPS Cell Differentiation

